Infection with hepatitis B virus (HBV) is a major cause of liver disease worldwide and affects more than 1 million people in the United States. Hepatitis induced by hepatitis B virus infection is a complex and intricate process involving interactions of multiple host factors with the virus and/or the viral gene products. The HBV X (HBV) gene plays a crucial role in the life cycle and oncogenic potential of HBV. Since virus-host interactions are central to the pathogenesis of viral infection and host injury, this project aims to elucidate the cellular and molecular mechanisms of HBX-host interactions during HBV infection. We have previously shown that HBX interacts with the proteasome complex in vitro and in vivo. The 26S proteasome complex is the predominant cellular machinery which degrades cellular proteins in both ubiquitin-dependent and -independent pathways. It has been implicated in the regulation of a variety of transcriptional and cell cycle factors, cellular stress response, and antigen presentation. HBX interacts with the proteasome subunits through a mutually competitive structural relationship. The crucial HBX sequences involved in the interaction with the proteasome complex are important for its function as a transcriptional coactivator. We have also shown that HBX functions as a substrate as well as an inhibitor of proteasome. Using the woodchuck model, we also demonstrated that the X-defective mutants of woodchuck hepatitis virus (WHV) are not completely replication defective, possibly behave like attenuated viruses in the woodchuck model. Animals inoculated with X mutants including those with no serologic evidence of infection were protected from the challenge, suggesting prior infection resulting protective immunity. To further study the role of the proteasome in the biology of HBX, we analyzed the effects of the proteasome inhibitors on the replication of wild-type and X-minus WHV and HBV using recombinant baculovirus or adenovirus expressing replicating HBV genome. We generated a recombinant baculovirus with CMV driven replication-competent WHV genome and another with the X-minus WHV genome by mutating the ATG start codon of the X gene to TTG. Recombinant adenoviruses expressing replicating HBV genome with and without a mutation inactivating the X gene were also used. In cells infected with either the recombinant baculovirus or adenovirus, the replication level of the X-minus construct was about 10% of that of the wild-type. When proteasome inhibitors were added, the replication of the wild-type virus was not affected, while the replication of the X-minus virus of either WHV or HBV was restored to the wild-type level. The inhibition of proteasome function by HBX may account for the multiple actions of HBX and may be an important feature of HBV infection, possibly in helping stabilize viral gene products and suppressing antigen presentation. Because of the importance of HBX in HBV life cycle, we aim to develop potential anti-HBV agents by targeting the functions of HBX using a random combinatorial approach. We developed a modified yeast two-hybrid disruptor system to screen a random peptide aptamer library which uses the bacterial protein TrxA as a platform to display the randomly synthesized peptide aptamers. The peptide aptamers which disrupted HBX-PSMA7 (a proteasome subunit) interaction were cloned into CMV expression vector for transfection studies. The effects of these peptide aptamers on HBX transaction, HBV replication, transcription, and antigen expression were characterized in HepG2 cells. By screening 1.5 x 107 yeast colonies with HBX and PSMA7 as interacting pair, and a random peptide aptamer library as disruptors, 367 yeast tranformants were isolated. On secondary screening, 21 colonies were confirmed to show specific disruption of the HBX-PSMA7 interaction. The peptide aptamers from these yeast colonies were isolated, sequenced, and cloned into a CMV-driven construct for transfection in HepG2 cells. Transactivation assays showed that these peptide aptamers could interfere with the effect of HBX transactivation on RSV-Luc reporter by increasing or decreasing the luciferase activities. When co-transfected with a HBV replication competent construct, many of the peptide aptamers which inhibited the HBX transactivation could suppress HBV DNA replication by about 50 to 60%. Our results demonstrate that selection of random peptide apatamers based on disruption of the HBX-proteasome interaction in a modified yeast two-hybrid system may identify potential therapeutic drugs for HBV infection.
| Yamaguchi, Ikuyo; Tchao, Bie Nga; Burger, Megan L et al. (2012) Vascular endothelial cadherin modulates renal interstitial fibrosis. Nephron Exp Nephrol 120:e20-31 |
| López-Guisa, Jesús M; Cai, Xiaohe; Collins, Sarah J et al. (2012) Mannose receptor 2 attenuates renal fibrosis. J Am Soc Nephrol 23:236-51 |
| Zhang, Guoqiang; Kernan, Kelly A; Thomas, Alison et al. (2009) A novel signaling pathway: fibroblast nicotinic receptor alpha1 binds urokinase and promotes renal fibrosis. J Biol Chem 284:29050-64 |
| Okamura, Daryl M; Pennathur, Subramaniam; Pasichnyk, Katie et al. (2009) CD36 regulates oxidative stress and inflammation in hypercholesterolemic CKD. J Am Soc Nephrol 20:495-505 |
| Eddy, Allison A (2009) Serine proteases, inhibitors and receptors in renal fibrosis. Thromb Haemost 101:656-64 |
| Loomba, Rohit; Rowley, Ayana; Wesley, Robert et al. (2008) Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 148:519-28 |
| Pawlotsky, Jean-Michel; Dusheiko, Geoffrey; Hatzakis, Angelos et al. (2008) Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 134:405-15 |
| Hoofnagle, Jay H; Doo, Edward; Liang, T Jake et al. (2007) Management of hepatitis B: summary of a clinical research workshop. Hepatology 45:1056-75 |
| Ghany, Marc; Liang, T Jake (2007) Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 132:1574-85 |
| Loomba, Rohit; Liang, T Jake (2007) Treatment of chronic hepatitis B. Antivir Ther 12 Suppl 3:H33-41 |
Showing the most recent 10 out of 21 publications
